Drug Profile
Prostaglandin E EP4 receptor antagonist - Eli Lilly and Company
Alternative Names: EP4-R Antagonist - Eli Lilly and CompanyLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Small molecules
- Mechanism of Action Prostaglandin E EP4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Musculoskeletal pain; Osteoarthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Musculoskeletal-pain in USA
- 04 Nov 2017 No recent reports of development identified for phase-I development in Osteoarthritis in USA
- 23 Jan 2014 Phase-I clinical trials in Musculoskeletal pain in USA (unspecified route)